KRAS across 13 cancers
KRAS is on the target list of 13 of the briefings. A drug aimed at it carries an FDA label naming the disease in 2, and is approved for some indication in 13. In the reference cohorts of the 13 with a mutation landscape it is altered in at least 5% of patients in 13.
| Disease | Label status | Furthest stage (Open Targets) | Distinct drugs | Cell-therapy trials | Altered in the reference cohort |
|---|---|---|---|---|---|
| Colorectal cancer | approved here Adagrasib, Sotorasib | approved | 3 | — | 40.82% mut · 1.01% amp · 0.17% del n=534 |
| Lung cancer | approved here Adagrasib, Sotorasib | approved | 3 | — | 29.68% mut · 5.68% amp n=566 |
| Pancreatic cancer | approved elsewhere | approved | 3 | 2 via KRAS G12D | 65.36% mut · 4.37% amp n=179 |
| Cervical cancer | approved elsewhere | approved | 3 | — | 5.15% mut · 0.68% amp n=291 |
| Cholangiocarcinoma | approved elsewhere | approved | 3 | — | 18.23% mut n=417 |
| Esophageal cancer | approved elsewhere | approved | 3 | — | 1.1% mut · 7.14% amp · 0.55% del n=182 |
| Gallbladder cancer | approved elsewhere | approved | 3 | — | 7.73% mut · 4.29% amp n=233 |
| Gastric cancer | approved elsewhere | approved | 3 | — | 9.17% mut · 7.99% amp n=436 |
| Multiple myeloma | approved elsewhere | approved | 3 | — | 21.95% mut n=205 |
| Ovarian cancer | approved elsewhere | approved | 3 | — | 1.15% mut · 9.44% amp n=523 |
| Rhabdomyosarcoma | approved elsewhere | approved | 3 | — | 6.98% mut n=43 |
| Small intestine cancer | approved elsewhere | approved | 3 | — | 46.71% mut · 1.32% amp n=152 |
| Testicular cancer | approved elsewhere | approved | 3 | — | 8.05% mut · 8.72% amp n=149 |
"Approved here" means a drug Open Targets records as aimed at KRAS carries an FDA label that names that disease, per the briefing's openFDA stage. "Approved elsewhere" means the drug is approved for some other indication. Stage is the furthest Open Targets clinical stage among drugs aimed at the gene, in any indication; the database is reported as it is, and it lags some approvals. Cell-therapy trials are counted on the antigen the briefing maps the gene to, from ClinicalTrials.gov. The last column is the disease's mutation landscape: non-silent mutation, high-level amplification and deep deletion as percentages of the reference cohort's patients, each over its own denominator; "not on panel" means the reference cohort could not have called the gene.